Bharat Biotech International Ltd. has successfully developed India’s first indigenous vaccine candidate for COVID-19 to enter human trials. Named Covaxin, the vaccine has been cleared by the Drug Controller General of India (DCGI) and Ministry of Health & Family Welfare for phase I and II trials after the company submitted positive preclinical study results regarding safety and immune response. Read More

HONG KONG – Japan’s Ministry of Health, Labour and Welfare (MHLW) ended the first half of 2020 by handing out a flurry of approvals to both domestic and international companies across a wide spectrum of indications. Read More

HONG KONG – SK Biopharmaceuticals Co Ltd.’s shares are still basking in the afterglow of a successful entrance on the Korea Exchange, which raised ?959.30 billion (US$799 million). Read More

HONG KONG - Ocumension Therapeutics Ltd., a China-based ophthalmic pharmaceutical company, launched its IPO on the Hong Kong Exchange (HKEX) this week. The company seeks to raise more than HK$1.5 billion (US$190 million). Read More

A large epidemiological study published in the July 6, 2020, advance online issue of The Lancet found that most individuals who became infected with SARS-CoV-2 developed antibodies to the virus, confirming that infection usually results in at least a short-term immune response. Read More

Research focused on finding viable solutions to counter the COVID-19 pandemic continues at an explosive pace with a total of 588 potential therapeutics and vaccines at the forefront of scientific efforts launched by industry, academia and government. Read More

Carmine Therapeutics Inc. said Tuesday that Takeda Pharmaceutical Co. Ltd. has engaged it in a research collaboration aimed at the discovery, development and commercialization of new nonviral gene therapies for two rare disease targets. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Affinity, Aim Immunotech, Aligos, Anivive Lifesciences, Ascentage, Binx Health, Blueprint Medicines, Burning Rock, Cstone, Curevac, Cytodyn, Dr. Reddy's, Eisai, Emergent Biosolutions, Epicentrx, Fibrogenesis, Fujifilm, Fusion Antibodies, Hitachi, Hitgen, Hoth, Immune Regulation, Inimmune, Johnson & Johnson, Liminal, Medivir, Meissa Vaccines, Merck, Morphic, Myneo, Nyrada, Optinose, Ridgeback, Sciclone, Sherlock, Shionogi, Sorrento, Sumitomo Dainippon, Thinkcyte, Ziphius. Read More

Biopharmas in Asia-Pacific raising money in public or private financings, including: CF Pharmtech, Taiwan Liposome. Read More

The latest global regulatory news, changes and updates affecting biopharma, including: Apotex, DoJ, EMA, Glenmark, U.S. House, Senate, South Korea’s Ministry of Food and Drug Safety, Trump administration. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: 4D Pharma, Abivax, Biontech, CSL Behring, Daiichi Sankyo, Depuy Synthes Products, Durect, Inovio, Oncolys, Orthocell, Pfizer, Regeneron, Sanofi, Timber, Transcenta. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Alterity, Astrazeneca, Beigene, Biophytis, Daiichi Sankyo, Eusa, Gilead Sciences, Golden, Hangzhou Yuyuan, Medicinova, Merck, Mesoblast, Mezzion, Mylan, Nuvox, Obseva, Prestige, Revive, Sinovac, TC Biopharm. Read More